Adaptive Biotechnologies

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell ADPT and other ETFs, options, and stocks.

About ADPT

Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines.

CEO

Chad Robins

CEOChad Robins

Employees

624

Employees624

Headquarters

Seattle, Washington

HeadquartersSeattle, Washington

Founded

2009

Founded2009

Employees

624

Employees624

ADPT Key Statistics

Market cap

2.35B

Market cap2.35B

Price-Earnings ratio

-44.87

Price-Earnings ratio-44.87

Dividend yield

—

Dividend yield—

Average volume

1.89M

Average volume1.89M

High today

$15.06

High today$15.06

Low today

$14.22

Low today$14.22

Open price

$14.58

Open price$14.58

Volume

1.95M

Volume1.95M

52 Week high

$20.76

52 Week high$20.76

52 Week low

$8.50

52 Week low$8.50

Stock Snapshot

The current Adaptive Biotechnologies(ADPT) stock price is $14.69, with a market capitalization of 2.35B. The stock trades at a price-to-earnings (P/E) ratio of -44.87.

On 2026-05-08, Adaptive Biotechnologies(ADPT) stock traded between a low of $14.22 and a high of $15.06. Shares are currently priced at $14.69, which is +3.3% above the low and -2.5% below the high.

The Adaptive Biotechnologies(ADPT)'s current trading volume is 1.95M, compared to an average daily volume of 1.89M.

During the past year, Adaptive Biotechnologies(ADPT) stock moved between $8.50 at its lowest and $20.76 at its peak.

ADPT News

TipRanks 23h

Adaptive Biotechnologies price target lowered to $19 from $21 at JPMorgan

JPMorgan lowered the firm’s price target on Adaptive Biotechnologies (ADPT) to $19 from $21 and keeps an Overweight rating on the shares. The firm updated the c...

Simply Wall St 1d

How Strong MRD Growth and Upgraded 2026 Guidance Will Impact Adaptive Biotechnologies Investors

In the past quarter, Adaptive Biotechnologies reported first‑quarter 2026 revenue of US$70.87 million, up from US$52.44 million a year earlier, while narrowing...

TipRanks 2d

Adaptive Biotechnologies Leans on MRD in Earnings Call

Adaptive Biotechnologies ((ADPT)) has held its Q1 earnings call. Read on for the main highlights of the call. Claim 55% Off TipRanks Unlock hedge fund-level dat...

Analyst ratings

88%

of 8 ratings

Buy

87.5%

Hold

12.5%

Sell

More ADPT News

Nasdaq 3d

Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.

Key Points COO Julie Rubinstein sold 19,037 shares for a transaction value of ~$271,000 on April 27, 2026, at a weighted average price of around $14.23 per sha...

Simply Wall St 5d

Assessing Adaptive Biotechnologies Valuation After Recent Share Price Weakness

Advertisement What recent performance says about Adaptive Biotechnologies Adaptive Biotechnologies (ADPT) has drawn fresh attention after a mixed stretch in t...

People also own

Based on the portfolios of people who own ADPT. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.